Konfer Launches DORA Compliance Controls Catalog to Help EU Meet January 2025 Compliance Deadline, Partners With Leading Law Firm Osborne Clarke to Offer DORA Compliance Check to EU Organizations
10.9.2024 10:00:00 CEST | Business Wire | Press release
Konfer, the Silicon Valley-based Agentic AI product company, today announced the launch of the Konfer DORA Compliance Controls Catalog to help EU financial institutions meet the January 2025 conformance deadline.
The Konfer DORA Control Questions Catalog is designed to guide financial institutions through the complexities of the Digital Operational Resilience Act (DORA). Konfer’s AI agent has interpreted DORA’s extensive regulation, converting the obligations into practical control questions. These questions not only assess compliance but also integrate team responses to provide a detailed view of an organization's operational resilience, identifying potential vulnerabilities, and enhancing risk management processes.
“The Konfer DORA Controls Catalog was designed to help EU financial institutions not just get a translation of the DORA compliance, but to actively implement the controls across their teams and operationalize compliance,” said Debu Chatterjee, CEO of Konfer. “It takes out guess-work or interpretation gaps, and empowers ICT and compliance leaders with a rubric for conformance, with the shortest time-to-value, given the approaching January 2025 deadline.”
IT leaders and Compliance executives in the EU financial institutions are required to specify the elements which a financial entity needs to determine and assess when subcontracting ICT services supporting critical or important functions. This puts the burden of collecting responses from third party vendors, analyzing the responses, and identify vulnerabilities on the financial institution. “With Konfer Clear for DORA, executive leadership can now gain complete visibility into their third-party vendors’ compliance, and proactively require them to upgrade and maintain their resiliency,” continued Chatterjee. “Our focus is to help operationalize compliance—whether internally or with external vendors—so that the compliance teams are able to focus on risk analysis, vulnerability assessments, and proactive remediation rather than on repetitive tasks.”
Konfer has partnered with leading law firm Osborne Clarke Netherlands to develop DORA Compliance Check for the firm’s clients. The law firm will leverage Konfer Clear to provide clients with advice on their DORA Compliance requirements, gaps, and confidence score.
“We are pleased to partner with Konfer, and look forward to enabling our clients to accelerate their DORA compliance time-to-completion, using Konfer Clear,” said Johannes de Jong, Financial Regulatory partner at Osborne Clarke Netherlands. “This online tool will help our clients to rapidly upload their compliance documents and receive a Clear scorecard, thereby providing valuable insights for their ICT contract management.”
Konfer DORA Compliance Controls is easily embedded into workflows, and is able to connect with the financial institutions internal and external ICT systems. The AI-powered suite is able to rapidly analyze gaps, compare with any new updates to the compliance mandates, and alert IT and compliance leaders.
The DORA Compliance Controls can be downloaded from https://konfer.ai/acts/finance/
About Konfer: Based in Milpitas, CA, Konfer is a venture-backed Agentic AI product that delivers governance workflows to manage the explosion of regulations across the world in a standard scalable way.
About Osborne Clarke: Osborne Clarke is an international, full-service law firm with over 330 partners and more than 1,630 legal experts working across 26 global locations. We combine the personalised service of a local office with the resources and reach of a large international firm, providing effective solutions for complex issues. Osborne Clarke has an impressive client base in the sectors of Energy & Utilities, Financial Services, Life Sciences & Healthcare, Mobility & Infrastructure, Retail & Consumer, Tech, Media & Comms, The Built Environment, and Workforce Solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910605198/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release
The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 14:00:00 CET | Press release
• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years • 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion • 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expa
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom